Europe's AgTech Leader Is Losing Its Edge—Here's Why

Jan de Vries · 2026-10-30

The Netherlands has long been the quiet powerhouse of European food and agricultural innovation. But a new report from Invest-NL, the Dutch national investment institution, suggests that crown is starting to slip. And the implications stretch far beyond one small country. According to the Deep Dive Agrifood Biotech report, tackling the barriers facing Dutch agrifood biotech companies could unlock roughly $18.5 billion in extra annual revenue by 2040. That's a huge number. But without coordinated action on regulation, financing, and commercialization, most of that opportunity will likely be captured elsewhere. The study draws on interviews with over 150 entrepreneurs, investors, researchers, and policymakers, plus investment data from 2010 through April 2026. It zeroes in on three strategic areas: seed breeding and genetics, biological agricultural inputs, and biotech-derived food ingredients. ### A strong start, a weaker finish The Netherlands has world-class agricultural research institutions, established seed breeders, and a sophisticated food production ecosystem. So why isn't that scientific excellence translating into globally competitive businesses? The report points to a telling imbalance: the Netherlands accounts for 3.3% of BioTech startups worldwide, but only 1.3% of scale-ups, according to data from TNO (the Netherlands Organisation for Applied Scientific Research). In plain terms, the country is great at generating innovation but struggles to help young companies reach meaningful commercial scale. Invest-NL identifies three recurring weaknesses: - Too few promising technologies become scalable ventures - Regulatory and validation processes delay market entry - Insufficient financing prevents companies from reaching industrial production And the stakes are high. In a favorable scenario, annual Dutch agrifood BioTech revenues could reach about $27 billion by 2040. Under current conditions, they'd sit at just $8.7–9.8 billion. Crucially, the report argues the Netherlands doesn't need to manufacture everything domestically. Instead, it should focus on retaining strategically valuable knowledge, intellectual property, companies, and specialized capabilities—while tapping into European production networks where it makes sense. ### Ten years to say yes One of the most striking obstacles involves biological crop protection, where Dutch companies are developing alternatives to conventional chemical pesticides. Getting European regulatory approval for a new biological crop protection product can take eight to ten years. Existing frameworks were largely designed around chemical products, making them a poor fit for certain biological innovations. As a result, some companies prioritize launching in markets like Brazil and the United States, where commercialization moves faster. Invest-NL warns that Europe risks losing ground in a biological crop protection market that could expand seven- to tenfold by 2040. Food biotechnology faces similar headaches. Regulatory approval for novel ingredients can take one to three years longer in Europe than in the United States, while building a first commercial production facility can require tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, Invest-NL estimates that favorable conditions could support about $8.7 billion in annual Dutch revenues by 2040, compared with around $2.2 billion under existing policies. The report stresses that faster approvals shouldn't come at the expense of safety. Instead, regulators should offer earlier guidance, more predictable assessments, and opportunities for companies to validate products under real-world conditions. ### What this means for the broader startup scene This isn't just an AgriTech story. It's a familiar pattern across European deep tech: strong science, weak scale-up. The Netherlands' struggle to turn research into revenue mirrors challenges faced by biotech, cleantech, and advanced manufacturing startups across the continent. For founders and investors watching EU Inc news, the lesson is clear. Regulatory speed and access to scale-up capital remain decisive factors in where companies choose to grow. And right now, Europe is losing that race more often than it wins. > "Innovation is not the issue," the report notes. The issue is everything that comes after. If the Netherlands—and Europe more broadly—wants to keep its competitive edge, it will need to move faster on approvals, smarter on financing, and more coordinated on commercialization. Otherwise, the next generation of agricultural breakthroughs will be invented in Europe but scaled somewhere else.